HRPK20040372B3 - Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist - Google Patents

Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist

Info

Publication number
HRPK20040372B3
HRPK20040372B3 HR20040372A HRP20040372A HRPK20040372B3 HR PK20040372 B3 HRPK20040372 B3 HR PK20040372B3 HR 20040372 A HR20040372 A HR 20040372A HR P20040372 A HRP20040372 A HR P20040372A HR PK20040372 B3 HRPK20040372 B3 HR PK20040372B3
Authority
HR
Croatia
Prior art keywords
telmisartan
sodium salt
same
crystalline sodium
angiotensin antagonist
Prior art date
Application number
HR20040372A
Other languages
Croatian (hr)
Inventor
Donsbach Kai
Hof Irmgard
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7704331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRPK20040372(B3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg.
Publication of HRP20040372A2 publication Critical patent/HRP20040372A2/en
Publication of HRPK20040372B3 publication Critical patent/HRPK20040372B3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Kristalinična natrijeva sol telmisartana formule I. naznačena time, da ima talište pri T = 245±5°C.Patent sadrži još 10 patentnih zahtjeva.The crystalline sodium salt of telmisartan of formula I having a melting point of T = 245 ± 5 ° C. The patent comprises 10 further claims.

HR20040372A 2001-10-31 2004-04-26 Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist HRPK20040372B3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10153737A DE10153737A1 (en) 2001-10-31 2001-10-31 Crystalline sodium salt of telmisartan, process for its preparation and its use for the manufacture of a medicament
PCT/EP2002/011394 WO2003037876A1 (en) 2001-10-31 2002-10-11 Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist

Publications (2)

Publication Number Publication Date
HRP20040372A2 HRP20040372A2 (en) 2004-10-31
HRPK20040372B3 true HRPK20040372B3 (en) 2006-02-28

Family

ID=7704331

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040372A HRPK20040372B3 (en) 2001-10-31 2004-04-26 Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist

Country Status (35)

Country Link
EP (1) EP1442023B1 (en)
JP (1) JP5124076B2 (en)
KR (1) KR100929502B1 (en)
CN (1) CN100509789C (en)
AR (1) AR037148A1 (en)
AT (1) ATE370125T1 (en)
AU (1) AU2002338886B2 (en)
BR (1) BR0213568A (en)
CA (1) CA2463146C (en)
CO (1) CO5580785A2 (en)
CY (1) CY1107504T1 (en)
DE (2) DE10153737A1 (en)
DK (1) DK1442023T3 (en)
EA (1) EA007596B1 (en)
EC (1) ECSP045089A (en)
ES (1) ES2291505T3 (en)
HK (1) HK1073841A1 (en)
HR (1) HRPK20040372B3 (en)
HU (1) HUP0402391A3 (en)
IL (2) IL161165A0 (en)
ME (1) MEP43608A (en)
MX (1) MXPA04004013A (en)
MY (1) MY129741A (en)
NO (1) NO326465B1 (en)
NZ (1) NZ532716A (en)
PE (1) PE20030629A1 (en)
PL (1) PL211462B1 (en)
PT (1) PT1442023E (en)
RS (1) RS50879B (en)
SA (1) SA02230419B1 (en)
SI (1) SI1442023T1 (en)
TW (2) TWI341200B (en)
UA (1) UA82833C2 (en)
UY (1) UY27520A1 (en)
WO (1) WO2003037876A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
DE10319450A1 (en) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical formulation of telmisartan sodium salt
EP1713795A2 (en) 2004-02-11 2006-10-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
KR20090029310A (en) * 2004-05-05 2009-03-20 테바 파마슈티컬 인더스트리즈 리미티드 Preparation of candesartan cilexetil in high purity
WO2006044754A2 (en) 2004-10-18 2006-04-27 Dr. Reddy's Laboratories Ltd. Process for preparing telmisartan
WO2006050509A2 (en) * 2004-11-03 2006-05-11 Teva Pharmaceutical Industries Ltd. Amorphous and polymorphic forms of telmisartan sodium
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2151450A1 (en) * 2008-07-29 2010-02-10 Sandoz AG Method for processing microbiologically produced cyclic oligopeptides
PL2432452T3 (en) 2009-05-20 2017-07-31 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical telmisartan drink solution
EP2448575A2 (en) 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
EP2448576A2 (en) 2009-07-02 2012-05-09 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2632438A1 (en) 2010-10-27 2013-09-04 KRKA, tovarna zdravil, d.d., Novo mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
CN103619556B (en) * 2011-06-24 2016-12-07 本田技研工业株式会社 Injection molding method and device thereof
UA120278C2 (en) 2011-11-25 2019-11-11 Адверіо Фарма Гмбх SUBSTITUTED 5-FLUORINE-1H-PYRAZOLOPYRIDINES IN CRYSTAL FORM
US10385078B2 (en) 2014-10-21 2019-08-20 Ariad Pharmaceuticals, Inc. Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
KR101872726B1 (en) * 2016-07-28 2018-06-29 주식회사 씨트리 Telmisartan methanesulfonate and pharmaceutical composition comprising the same
NZ759782A (en) 2017-07-07 2023-06-30 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
JP2022517610A (en) * 2019-01-10 2022-03-09 シーエスピーシー ゾンチー ファーマシューティカル テクノロジー（シージアチュアン）カンパニー，リミテッド Heterocyclic compound salts and their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9210098B (en) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoles, drugs with this compounds, and process for their preparation
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
JP4369994B2 (en) * 1996-02-29 2009-11-25 ノバルティス アクチエンゲゼルシャフト AT for lowering apoptosis 1 Receptor antagonist
DE19901921C2 (en) * 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphs of telmisartan, process for their preparation and their use in the manufacture of a medicament

Also Published As

Publication number Publication date
DK1442023T3 (en) 2007-11-05
IL161165A (en) 2009-12-24
HUP0402391A2 (en) 2005-03-29
TWI333419B (en) 2010-11-21
PE20030629A1 (en) 2003-07-14
JP5124076B2 (en) 2013-01-23
ES2291505T3 (en) 2008-03-01
UY27520A1 (en) 2003-05-30
DE10153737A1 (en) 2003-05-28
CY1107504T1 (en) 2013-03-13
YU36304A (en) 2006-08-17
CN100509789C (en) 2009-07-08
EP1442023A1 (en) 2004-08-04
SA02230419B1 (en) 2007-07-31
KR100929502B1 (en) 2009-12-03
AU2002338886B2 (en) 2008-04-17
CA2463146C (en) 2011-01-25
HUP0402391A3 (en) 2010-03-29
CN1578772A (en) 2005-02-09
IL161165A0 (en) 2004-08-31
SI1442023T1 (en) 2007-12-31
PT1442023E (en) 2007-09-17
MXPA04004013A (en) 2004-06-18
TW200300082A (en) 2003-05-16
HRP20040372A2 (en) 2004-10-31
PL367477A1 (en) 2005-02-21
MY129741A (en) 2007-04-30
EP1442023B1 (en) 2007-08-15
ATE370125T1 (en) 2007-09-15
JP2005536445A (en) 2005-12-02
NO20041758L (en) 2004-04-29
AR037148A1 (en) 2004-10-27
EA200400479A1 (en) 2004-10-28
WO2003037876A1 (en) 2003-05-08
MEP43608A (en) 2011-02-10
CO5580785A2 (en) 2005-11-30
TW201034664A (en) 2010-10-01
PL211462B1 (en) 2012-05-31
TWI341200B (en) 2011-05-01
UA82833C2 (en) 2008-05-26
HK1073841A1 (en) 2005-10-21
DE50210719D1 (en) 2007-09-27
KR20050035172A (en) 2005-04-15
ECSP045089A (en) 2004-06-28
RS50879B (en) 2010-08-31
EA007596B1 (en) 2006-12-29
BR0213568A (en) 2004-09-08
NZ532716A (en) 2007-06-29
NO326465B1 (en) 2008-12-08
CA2463146A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
HRPK20040372B3 (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
RS51444B (en) Lactam-containing compounds and derivatives thereof as factor xa inhibitors
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
PT1109812E (en) PYRROLOBENZODIAZEPINAS
RS49673B (en) Nitric oxide synthase inhibitors
HN2002000028A (en) METALOPROTEINASH INHIBITING PYRIMIDINS
ATE302775T1 (en) CARBOLINE DERIVATIVES
NO20041504L (en) Lactam derivatives as antagonists of human 11CBY receptors.
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
HRP20010573B1 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
DK1177176T3 (en) Triarylic acid derivatives as PPAR receptor ligands
CY1109886T1 (en) New compounds as anti-inflammatory, immunomodulatory and anti-hypoplastic agents
CY1106247T1 (en) THIOPHEN- AND THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS
BR0313420A (en) Microbicidal Quinolones, their compositions and uses
ATE403429T1 (en) SPIROPYRAZOLE COMPOUNDS
BR0014651A (en) Beta2-mediated cell adhesion inhibitors
ES2189968T3 (en) Amidinophenyl-pyrrolidines, -pyrrolines, e -isoxazolidines and derivatives thereof.
ES2421948T3 (en) Compounds and compositions for delivering active agents
RS53428B (en) Compositions and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
ES2187261B2 (en) ETERES AND AMIDAS COMPOUNDS AND THEIR PREPARATION, AS ANTI-DIABETIC AGENTS.
TR199902283T2 (en) Substituted isoquinoline derivatives and their use as anticonvulsants.
TR200403436T2 (en) Crystalline 1-methylcarbapenem derivatives.
RS53211B (en) PYRIDO[2,3-d]PYRIMIDINE DERIVATIVES, PROCES FOR THEIR PREPRATION AND THEIR THERAPEUTICAL USE
AU2002338886A1 (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
TR200001452T2 (en) Biphenylamidine derivatives.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AKOB Publication of a request for the grant of a patent not including a substantive examination of a patent application (a consensual patent)
PKB1 Consensual patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20120926

Year of fee payment: 11

PK10 Patent expired after termination of 10 years for consensual patent

Effective date: 20121012